Loading...
NPI 1861900698 · Homewood, AL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Lab Works, LLC is a clinical medical laboratory provider located in Homewood, Alabama. This profile covers 45 Medicare and 128 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Lab Works, LLC |
| Address | 100 Oxmoor Blvd, Suite 190 |
| City | Homewood |
| State | AL |
| ZIP | 35209 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 15, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $41.6M |
| Medicare | $738.4K |
LAB WORKS, LLC is operating primarily as a high-volume molecular and infectious disease testing laboratory with substantial volume in multiplex nucleic acid tests and SARS-CoV-2 related assays; Medicaid top codes show especially large volumes for respiratory virus panels (87633) and unspecified amplified probe tests (87798), while Medicare top codes emphasize definitive drug testing (G0483) and multi-pathogen nucleic acid tests (87507, 87631), indicating a dual focus on infectious disease diagnostics and definitive toxicology.
Revenue is heavily concentrated by payer: Medicare revenue totals $738.4K with the precomputed top 3 Medicare codes accounting for 78.4% of that Medicare revenue, driven mainly by G0483, 87507 and 87631; Medicaid revenue is much larger at $41.6M with the precomputed top 3 Medicaid codes accounting for 61.1% of Medicaid revenue, led by 87633, 87798 and U0004.
The provider is effectively Medicaid-dominant in scale: reported Medicaid revenue ($41.6M) far exceeds Medicare revenue ($738.4K), so operational scale, capacity and market footprint appear focused on state Medicaid flows rather than traditional Medicare business. This suggests payer mix and cash flow are materially dependent on Medicaid contracts and claim volumes.
Competitive standing differs by payer and code: on Medicare, G0483 revenue ($352.6K, ranks #72 of 1063, 93rd percentile) and 87631 (93rd percentile) place LAB WORKS at or above typical national volume for those codes but not among the very largest national players; by contrast, on Medicaid several core codes are state outliers — 87633 ranks #3 of 98 (98th percentile), 87798 ranks #4 of 57 (95th percentile), and U0004 ranks #2 of 15 (93rd percentile) — together indicating a dominant in-state position for high-throughput respiratory and COVID testing.
Specific Medicaid code-level outlier signals point to very large state volume for respiratory and COVID testing: 87633 is described as a 98th percentile result and 87634 and 87502 are called extreme outliers (98th percentile rank and extreme outlier language), while G2023 (specimen collection) ranks #1 of 148 in-state (100th percentile) — these labels and ranks indicate the provider is an unusually large processor of respiratory and SARS-CoV-2 specimens in Alabama Medicaid.
Service-line implications from the code mix support a lab setup optimized for high-throughput molecular platforms and centralized specimen handling: high volumes of multiplex nucleic acid amplification tests (87633, 87798, 87635, 87502, 87634) plus a large count of U0004/U0005 and G2023 specimen-collection claims imply automated molecular workflows and logistics for mass testing rather than a low-volume, clinic-based lab performing routine chemistry panels.
Medicare toxicology activity is notable but proportionally smaller relative to Medicaid: G0483 accounts for $352.6K (48.1% of Medicare revenue) and ranks in the 93rd percentile nationally, indicating meaningful definitive drug-testing capacity on the Medicare side even though overall Medicare revenue is small compared with Medicaid. This suggests the lab provides specialty toxicology services to some Medicare payers while Medicaid drives the primary volume.
Tenure is established but relatively recent: the NPI was enumerated on 2018-01-15 (~8 years ago), so the entity has built sizeable Medicaid testing volume within a relatively short operational window, consistent with growth during the pandemic and expansion into high-throughput respiratory testing services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
45 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,460 | $240 | $352.6K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 320 | $410 | $128.9K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 670 | $140 | $93.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 510 | $60 | $31.2K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 860 | $30 | $29.2K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 720 | $30 | $24.4K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 450 | $50 | $22.6K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 170 | $70 | $12.4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 50 | $110 | $5.2K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 130 | $30 | $4.1K |
Showing 1–10 of 45
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
128 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 65,030 | $180 | $12M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 61,130 | $140 | $8.6M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 84,980 | $50 | $4.2M |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 46,050 | $40 | $1.9M |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 45,630 | $40 | $1.8M |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 32,520 | $40 | $1.3M |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 54,310 | $20 | $1.2M |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 53,980 | $20 | $1.2M |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 41,790 | $20 | $1M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 61,990 | $20 | $991.9K |
Showing 1–10 of 128
How this provider's Medicaid billing volume and revenue compare to other Alabama providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Alabama median
128 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 4 | 60 | 1,260 | $60 | $1.2M |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 3 | 100 | 470 | $130 | $1.2M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 2 | 20 | 10,040 | $40 | $825.9K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 7 | 10 | 1,020 | $110 | $784.5K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 6 | 40 | 450 | $20 | $591.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 11 | 40 | 460 | $20 | $584.1K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 8 | 40 | 1,540 | $10 | $397.4K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 19 | 40 | 430 | $10 | $391.5K |
| 88175 | The lab analyst performs the technical lab test to analyze a cervical or vaginal cytopathology specimen that a clinician collected in preservative fluid. The test uses automated thin layer… | 17 | 20 | 1,500 | $20 | $389.4K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 4 | 40 | 1,440 | $20 | $372.1K |
Showing 1–10 of 128
Other providers in the same ZIP code as Lab Works, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.